Trump seeking economic deal with China as fresh trade talks loom- WSJ
Profound Medical (TASE:BLWV) Corp (NASDAQ: PROF), a medical technology company specializing in therapeutic ultrasound, has seen its stock price touch a 52-week low of $5.62. The company, with a market capitalization of $186 million, maintains strong liquidity with a current ratio of 10.52 and more cash than debt on its balance sheet, according to InvestingPro data. This latest price level reflects a significant downturn from previous periods, marking a challenging phase for the company’s market valuation. Over the past year, Profound Medical’s stock has experienced a notable decline, with a 1-year change showing a decrease of -28.25%, despite impressive revenue growth of 48.35%. This downturn highlights the volatility and the pressures faced by the healthcare sector, as well as investor sentiment towards the company’s performance and future prospects. For deeper insights into PROF’s valuation and 12+ additional ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Profound Medical Corp. has made significant financial adjustments, correcting a previously overstated revenue figure by $472,000 for the first quarter of 2024. This correction was part of an amended report filed with the U.S. Securities and Exchange Commission, transitioning their financial statements from International Financial Reporting Standards (IFRS) to U.S. Generally Accepted Accounting Principles (GAAP). The revised financials reflect Profound Medical’s commitment to accuracy and transparency in its reporting. In their fourth-quarter 2024 earnings report, the company announced a revenue of $4.2 million, marking a 108% increase year-over-year, and an earnings per share (EPS) of $0.20, which significantly exceeded the forecasted EPS of -$0.35.
Stifel analysts have maintained a Buy rating for Profound Medical, setting a price target of $12.00, following the company’s strong financial performance. The earnings call highlighted the establishment of CMS reimbursement and anticipated growth in 2025, driven by their TULSA technology. Profound Medical has also outlined several commercial initiatives for 2025, including targeting top U.S. cancer centers and expanding their sales force. The company has made strategic hires from leading MedTech sales organizations to support these initiatives. These developments underscore Profound Medical’s strategic focus on expanding the reach of its technology and enhancing its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.